Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly
- PMID: 19093000
- PMCID: PMC2599885
- DOI: 10.1371/journal.pone.0003958
Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly
Abstract
Background: Impaired mitochondrial function and ectopic lipid deposition in skeletal muscle and liver have been linked to decreased insulin sensitivity. As growth hormone (GH) excess can reduce insulin sensitivity, we examined the impact of previous acromegaly (AM) on glucose metabolism, lipid storage and muscular ATP turnover.
Participants and methods: Seven AM (4f/3 m, age: 46+/-4 years, BMI: 28+/-1 kg/m(2)) and healthy volunteers (CON: 3f/4 m, 43+/-4 years, 26+/-2 kg/m(2)) matched for age and body mass underwent oral glucose testing for assessment of insulin sensitivity (OGIS) and ss-cell function (adaptation index, ADAP). Whole body oxidative capacity was measured with indirect calorimetry and spiroergometry. Unidirectional ATP synthetic flux (fATP) was assessed from (31)P magnetic resonance spectroscopy (MRS) of calf muscle. Lipid contents of tibialis anterior (IMCLt) and soleus muscles (IMCLs) and liver (HCL) were measured with (1)H MRS.
Results: Despite comparable GH, insulin-like growth factor-1 (IGF-I) and insulin sensitivity, AM had approximately 85% lower ADAP (p<0.01) and approximately 21% reduced VO(2)max (p<0.05). fATP was similarly approximately 25% lower in AM (p<0.05) and related positively to ADAP (r = 0.744, p<0.01), but negatively to BMI (r = -0.582, p<0.05). AM had approximately 3 fold higher HCL (p<0.05) while IMCLt and IMCLs did not differ between the groups.
Conclusions: Humans with a history of acromegaly exhibit reduced insulin secretion, muscular ATP synthesis and oxidative capacity but elevated liver fat content. This suggests that alterations in ss-cell function and myocellular ATP production may persist despite normalization of GH secretion after successful treatment of acromegaly.
Conflict of interest statement
Figures



Similar articles
-
What do magnetic resonance-based measurements of Pi→ATP flux tell us about skeletal muscle metabolism?Diabetes. 2012 Aug;61(8):1927-34. doi: 10.2337/db11-1725. Diabetes. 2012. PMID: 22826313 Free PMC article. Review.
-
No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy.J Clin Endocrinol Metab. 2014 Nov;99(11):4299-306. doi: 10.1210/jc.2014-2242. Epub 2014 Aug 22. J Clin Endocrinol Metab. 2014. PMID: 25148232
-
Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents.PLoS Med. 2005 Sep;2(9):e233. doi: 10.1371/journal.pmed.0020233. Epub 2005 Aug 16. PLoS Med. 2005. PMID: 16089501 Free PMC article. Clinical Trial.
-
Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes.J Intern Med. 2011 Feb;269(2):189-99. doi: 10.1111/j.1365-2796.2010.02298.x. J Intern Med. 2011. PMID: 21205021 Clinical Trial.
-
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Acta Diabetol. 2009. PMID: 19322513 Review.
Cited by
-
The intricate role of growth hormone in metabolism.Front Endocrinol (Lausanne). 2011 Sep 27;2:32. doi: 10.3389/fendo.2011.00032. eCollection 2011. Front Endocrinol (Lausanne). 2011. PMID: 22654802 Free PMC article.
-
Modular 31 P wideband inversion transfer for integrative analysis of adenosine triphosphate metabolism, T1 relaxation and molecular dynamics in skeletal muscle at 7T.Magn Reson Med. 2019 Jun;81(6):3440-3452. doi: 10.1002/mrm.27686. Epub 2019 Feb 22. Magn Reson Med. 2019. PMID: 30793793 Free PMC article.
-
What do magnetic resonance-based measurements of Pi→ATP flux tell us about skeletal muscle metabolism?Diabetes. 2012 Aug;61(8):1927-34. doi: 10.2337/db11-1725. Diabetes. 2012. PMID: 22826313 Free PMC article. Review.
-
Long-term Outcome of Body Composition, Ectopic Lipid, and Insulin Resistance Changes With Surgical Treatment of Acromegaly.J Endocr Soc. 2023 Feb 21;7(5):bvad028. doi: 10.1210/jendso/bvad028. eCollection 2023 Mar 6. J Endocr Soc. 2023. PMID: 36922916 Free PMC article.
-
Secondary diabetes mellitus in acromegaly.Endocrine. 2023 Jul;81(1):1-15. doi: 10.1007/s12020-023-03339-1. Epub 2023 Mar 8. Endocrine. 2023. PMID: 36882643 Free PMC article. Review.
References
-
- Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006;355:2558–2573. - PubMed
-
- Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667–674. - PubMed
-
- Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90:4081–4086. - PubMed
-
- Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102–152. - PubMed
-
- Moller N, Norrelund H. The role of growth hormone in the regulation of protein metabolism with particular reference to conditions of fasting. Horm Res. 2003;59(Suppl 1):62–68. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials